Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease

被引:23
|
作者
Mango, Robert L. [1 ]
Matteson, Eric L. [1 ,2 ]
Crowson, Cynthia S. [1 ,2 ]
Ryu, Jay H. [3 ]
Makol, Ashima [1 ,4 ]
机构
[1] Mayo Clin Coll Med & Sci, Div Rheumatol, Rochester, MN 55905 USA
[2] Mayo Clin Coll Med & Sci, Dept Hlth Sci Res, Rochester, MN USA
[3] Mayo Clin Coll Med & Sci, Div Pulm & Crit Care Med, Rochester, MN USA
[4] Mayo Clin, Dept Internal Med, Div Rheumatol, 200 1st St SW, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Systemic sclerosis; Interstitial lung disease; Non-specific interstitial pneumonia; Usual interstitial pneumonia; Mortality modeling; IDIOPATHIC PULMONARY-FIBROSIS; SCLERODERMA LUNG; RISK PREDICTION; STAGING SYSTEM; SURVIVAL; TRIALS; SMOKING; PLACEBO; TRENDS; COHORT;
D O I
10.1007/s00408-018-0126-6
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The gender, age, and lung physiology (GAP) model, interstitial lung diseases-GAP (ILD-GAP) model, and the smoking history, age, and diffusion capacity of the lung (SADL) model were compared using a systemic sclerosis-ILD (SSc-ILD) cohort to evaluate which best determined prognosis. The models were applied to a cohort of 179 patients with SSc seen at a tertiary care center within 1 year of ILD diagnosis. Demographics, clinical characteristics, and mortality were recorded. The performance of the models was assessed using standardized mortality ratios (SMR) of observed versus predicted outcomes for calibration and concordance (c)-statistics for discrimination. SSc-ILD patients with usual interstitial pneumonia (31, 17%) had a higher mortality than those with non-specific interstitial pneumonia (147, 83%) (hazard ratio 2.27; 95%CI 1.03-4.97). All 3 models had comparable discrimination (c = 0.72, 0.72, and 0.71, respectively). Regarding calibration, the ILD-GAP model underestimated mortality (SMR 1.50; 95%CI 1.05-2.14). Calibration was acceptable for SADL (SMR 1.00; 95%CI 0.70-1.44) and GAP (SMR 0.90; 95%CI 0.63-1.29). The SADL model underestimated mortality in Stage I ILD. The ILD-GAP model underestimated mortality, and the SADL model underestimated mortality in certain subgroups. However, the GAP model performed well in this cohort, providing the best prognostic information for SSc-ILD.
引用
收藏
页码:409 / 416
页数:8
相关论文
共 50 条
  • [21] Induced sputum as a method for detection of systemic sclerosis-related interstitial lung disease
    Yilmaz, Neslihan
    Abul, Yasin
    Bicakcigil, Muge
    Golabi, Pejman
    Celikel, Cigdem
    Karakurt, Sait
    Yavuz, Sule
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (07) : 1921 - 1925
  • [22] Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
    Moore, Owen A.
    Goh, Nicole
    Corte, Tamera
    Rouse, Hannah
    Hennessy, Oliver
    Thakkar, Vivek
    Byron, Jillian
    Sahhar, Joanne
    Roddy, Janet
    Gabbay, Eli
    Youssef, Peter
    Nash, Peter
    Zochling, Jane
    Proudman, Susanna M.
    Stevens, Wendy
    Nikpour, Mandana
    RHEUMATOLOGY, 2013, 52 (01) : 155 - 160
  • [23] \ Journal Club: Efficacy of Tocilizumab in Early Systemic Sclerosis-Related Interstitial Lung Disease
    Tiwari, Vivekanand
    Rigby, William F. C.
    ACR OPEN RHEUMATOLOGY, 2022, 4 (02) : 119 - 122
  • [24] The Ambitious Goal of Validating Prognostic Biomarkers for Systemic Sclerosis-related Interstitial Lung Disease
    Bonella, Francesco
    Caramaschi, Paola
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (07) : 1034 - 1036
  • [25] Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 (11) : 2045 - 2056
  • [26] A RETROSPECTIVE DESCRIPTIVE ANALYSIS OF SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE AND PULMONARY HYPERTENSION
    Rowe, Anthony
    Ratwani, Ankush
    Barnett, Scott
    King, Christopher
    Shlobin, Oksana
    Nathan, Steven
    CHEST, 2020, 158 (04) : 1878A - 1879A
  • [27] Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
    Volkmann, Elizabeth R.
    Roth, Michael
    Elashoff, Robert
    Clements, Philip J.
    Furst, Daniel E.
    Khanna, Dinesh
    Goldin, Jonathan
    Tashkin, Donald
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [28] Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
    Khedoe, Padmini
    Marges, Emiel
    Hiemstra, Pieter
    Ninaber, Maarten
    Geelhoed, Miranda
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [29] Occupational Exposures and Systemic Sclerosis-Related Lung Disease
    Volkmann, Elizabeth R.
    CHEST, 2022, 161 (04) : 874 - 875
  • [30] PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE AFTER THE LUNG TRANSPLANTATION: A RETROSPECTIVE STUDY
    Nakayama, Y.
    Nakashima, R.
    Handa, T.
    Ohsumi, A.
    Yamada, Y.
    Nakajima, D.
    Yutaka, Y.
    Tanaka, S.
    Hamada, S.
    Ikezoe, K.
    Tanizawa, K.
    Shirakashi, M.
    Hiwa, R.
    Tsuji, H.
    Kitagori, K.
    Akizuki, S.
    Yoshifuji, H.
    Date, H.
    Morinobu, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 160 - 161